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to excellent track ability, crossing proﬁle, visibility but at the cost of
diminished longitudinal strength. The Promus Element platform is
notorious for this. In present case, if wire would not have accidentally
removed, the case would have gone smooth. However, rewiring in
stented vessel should always be done with keeping in a mind that wire
might have passed in between the struts and stent may deform. Until,
you are doubly sure that the wire in lumen does not force any balloon,
IVUS catheter or other devices. A coaxial guiding catheter is also vital
component of smooth delivery of devices into coronary lumen distal
to lesions.HIGH RISK PATIENTS: DIABETES, HEART FAILURE, RENAL
FAILURE, OTHERS (TCTAP C-138 TO TCTAP C-144)
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[CLINICAL INFORMATION]
Patient initials or identiﬁer number. Registration number 3768/2014
Relevant clinical history and physical exam. A 50 years old male got
admitted into National Institute of Cardiovascular Diseases, Dhaka on
14th June 2014, diagnosed as Old MI (Inferior) with unstable angina.
Patient had H/O Acute MI (inferior) with primary PCI & stenting to LCX
on 23rd May,2010, H/O CABG on 24th Dec,2011, PTCA & Stenting to
distal LAD after LIMA-LAD graft and RSVG-OM graft on 2nd Nov, 2013.
Patient regularly followed up with good compliance but noticed chest
discomfort on minimal exertion for last one month.
Relevant test results prior to catheterization. Patient is hypertensive,
diabetic & dyslipidemic but well controlled. Echocardiography
revealed OMI (inferior) with septal hypokinesia & EF- 52%, HbA1TCTAP
C-5.6%, Serum creatinine- 0.6mg/dl, Total Cholesterol-165mg/dl,
Triglycerides-170mg/dl, LDL- 72mg/dl, HDL- 35mg/dl, ESR- 62mm/1st
hour, Hs-CRP- 6.0 mg/L (Low risk < 1.0 mg/L), Fibrinogen- 430mg/dl
(200 – 300mg/dl), Lipoprotein(a)- 9mg/dl (< 14mg/dL), Homocysteine -
22mmol/L (5 to15mmol/L).
Relevant catheterization ﬁndings. Coronary angiogram was done on 2nd
Nov 2013, revealed double vessel disease at native vessels (LAD: osteal
to mid part, long diffuse lesion 80-90%, LCX stent was patent, OM1:
proximal part 80-90% stenosis, OM2: proximal part 80-90% stenosis,
RCA-normal and non-dominant). Graft angiography showed 80-90 %
lesion at distal part of LAD after LAD –LIMA graft and 80-90% at
RSVG-OM2 graft.
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Procedural step. Patient had history of Primary PCI and Stenting to LCX
with Zotarolimus drug eluting 3.5mm x 15mm stent on 23rd May,2010.
Again coronary angiogram followed by CABG (LIMA- LAD & RSVG –OM)
was done on 24th December 2011 due to complaints of CCS class II
angina despite optimal medical therapy. Patient regularly followed up
with good compliance and diabetes was well controlled throughout the
years. But patient again admitted with severe chest discomfort, not
relieved by rest on 2nd November 2013. Then Coronary angiogram,
followed by PTCA & Stenting was done at same setting. PTCA and
stenting to native LAD (distal to LAD –LIMA graft) was done.Guide
catheter- IMA 7F was engaged at origin of LIMA and BMWwire crossed
the lesion. Zotarolimus Drug eluting 2.5mm x12mm stent was deployed
at 12 ATM. Then PTCA & Stenting to RSVG – OM graft was done. JR 6F
catheter was engaged at origin of RSVG graft and BMW wire crossed &2.5mm x 8mm BMS stent was deployed at 12 ATM. TIMI 3 ﬂow was
achieved in the both arteries without residual stenosis.
Now patient was advised for re-look CAG but patient was not
interested to do any procedure due to frustration.
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sively focus on risk factor modiﬁcation i.e control of hypertension,
hyperglycemia, dyslipidemia and thereby reducing only 40% of CVD
events, leaving 60% of CVD events to occur. Therefore new ap-
proaches should be undertaken to tackle CHD which kills millions of
people each year worldwide. The atherosclerotic plaque related
events reﬂecting the temporal changes i.e initiation, progression and
complication of lesions may serve as surrogate biomarkers for hard
clinical endpoints in interventional studies. Further search for new
biomarkers with high predictive value is needed to identify high risk
patients and thus allowing early intervention.
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[CLINICAL INFORMATION]
Patient initials or identiﬁer number. FM
Relevant clinical history and physical exam. A 50 year old man presented
with- - History of effort angina for last 6 months ( CCS class II ) - Risk
factor was diabetes, hypertension, dyslipidemia and smoking. Rele-
vant examination revealed no abnormality
Relevant test results prior to catheterization. EKG: No signiﬁcant abnor-
malities Echo: No regional or global LV wall motion abnormalities
Concentric LV hypertrophy EF: 62% Treadmill test is positive for
provocable myocardial Ischaemia
Relevant catheterization ﬁndings. LM relatively free of disease (Fig 1, 2)-
LAD: Long 85% narrowing in proximal and mid (Fig 1, 2) 75% nar-
rowing in LAD ostium and proximal segment - LCX: Big size vessel and
free of disease (Fig 1, 2)- RCA: Normal (Fig 3)[INTERVENTIONAL MANAGEMENT]
Procedural step. PCI to LAD – LM: Considering the complexity of the
coronary lesion we switched over to femoral route. 600 mg clopidogrel
6 hours before and heparin IA bolus j before the procedure to maintain
ACT around 300 seconds. LM is relatively disease free, angle of the
bifurcation with the LCx – angles <75, it would be great difﬁculty in
precise stent placement in LAD ostium and risk of plaque shift, we
decided to deploy the stenting from LAD with overlapping with distal
stent across the LCX back in LM. 7F sheath, JL 3.5, 7F guiding catheter
engaged in to LM, 0.014
̋
runthrough wire introduce in to distal LAD
across the lesion and another wire inserted in to LCX. Lesion predilated
by 2x20 mm balloon at 14 ATM. After predilatation patient developed
severe chest pain, hypotension with ST elevation. CAG showed no ﬂow
phenomena.(Fig.2). IC GP IIb IIIa receptor blocker boluses infused. 3.5 x
48 mm DES (Xience Xpedition) deployed across the lesion at 14 ATM
(Fig 2). Another 4 x 22 mm DES (Resolute Integrity) from LM to LAD
overlapping. Post dilatation by 3.5x12 mm NC balloon at 22-24 ATM
distal Stent and 4.5x12 mm NC proximal and LM at 18-22ATM with
excellent result with TIMI III ﬂow. (Figure 3). Hospital Course and
Follow up: Hospital course was uneventful, No major bleeding, Patient
was discharged with aspirin 150 mg OD and prasugrel 20 mg OD. At one
month follow up patient is totally symptom free.
